$1.35
1.46% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US0197701065
Symbol
ALLO

Allogene Therapeutics, Inc. Stock price

$1.35
+0.01 0.75% 1M
+0.15 12.50% 6M
-0.02 1.46% YTD
-0.85 38.64% 1Y
-4.94 78.54% 3Y
-24.44 94.77% 5Y
-23.65 94.60% 10Y
-23.65 94.60% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.02 1.46%
ISIN
US0197701065
Symbol
ALLO
Industry

Key metrics

Basic
Market capitalization
$303.4m
Enterprise Value
$51.2m
Net debt
positive
Cash
$252.2m
Shares outstanding
223.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 26,772.4
EV/Sales
- | 4,518.1
EV/FCF
negative
P/B
1.0
Financial Health
Equity Ratio
76.9%
Return on Equity
-61.0%
ROCE
-55.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $11.3k
EBITDA
$-212.5m | $-210.6m
EBIT
$-225.0m | $-223.2m
Net Income
$-212.0m | $-212.8m
Free Cash Flow
$-159.0m
Growth (TTM | estimate)
Revenue
-100.0% | -43.5%
EBITDA
57.3% | 13.6%
EBIT
56.0% | 13.3%
Net Income
59.6% | 17.4%
Free Cash Flow
27.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -1,858,712.9%
EBIT
-
Net
- | -1,878,079.2%
Free Cash Flow
-
More
EPS
$-1.0
FCF per Share
$-0.7
Short interest
9.7%
Employees
228
Rev per Employee
$0.0
Show more

Is Allogene Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Allogene Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Allogene Therapeutics, Inc. forecast:

16x Buy
80%
3x Hold
15%
1x Sell
5%

Analyst Opinions

20 Analysts have issued a Allogene Therapeutics, Inc. forecast:

Buy
80%
Hold
15%
Sell
5%

Financial data from Allogene Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 59 59
52% 52%
-
- Research and Development Expense 166 166
57% 57%
-
-212 -212
57% 57%
-
- Depreciation and Amortization 13 13
10% 10%
-
EBIT (Operating Income) EBIT -225 -225
56% 56%
-
Net Profit -212 -212
60% 60%
-

In millions USD.

Don't miss a Thing! We will send you all news about Allogene Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Allogene Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
19 days ago
Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Ce...
Neutral
GlobeNewsWire
about 2 months ago
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conference in November and December.
Positive
Seeking Alpha
about 2 months ago
Allogene Therapeutics, Inc. is downgraded from Strong Buy to Hold due to setbacks in its pivotal phase 2 ALPHA3 trial. ALLO's cema-cel for Large B-Cell Lymphoma remains on track for a key futility analysis in H1 2026, but must proceed without ALLO-647. ALLO-316 showed a 31% response rate in advanced RCC patients with CD70+ TPS ≥50%, but future studies will require this narrow focus.
More Allogene Therapeutics, Inc. News

Company Profile

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Head office United States
CEO David Chang
Employees 228
Founded 2017
Website allogene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today